Breaking News

Baxter Completes Gambro Acquisition

September 6, 2013

Enhances global renal portfolio of product and therapies

Baxter International, Inc. has completed the acquisition of Gambro AB, a global medical technology company based in Lund, Sweden, for approximately $3.9 billion, expanding its global renal business and gaining a comprehensive portfolio of product and therapies.
 
The acquisition provides a broad dialysis product portfolio and global footprint that will allow Baxter to grow product sales in Europe, where Gambro has an extensive presence, as well as Latin America and Asia-Pacific.
 
Brik Eyre has been named president of the combined Renal business and has been elected a corporate officer of Baxter. He reports to Robert M. Davis, president of Baxter’s Medical Products business. Mr. Eyre joined the company in 2008 and previously served as the general manager of U.S. Medication Delivery. Prior to this he served as general manager for Baxter’s BioPharma Solutions business.
 
“The combination of these two respected renal leaders will enable Baxter to better serve healthcare providers and patients through a collective offering of innovative renal products and therapies,” said Robert L. Parkinson, Jr., chairman and chief executive officer of Baxter. “Together, we will advance the state of dialysis care for patients with kidney disease worldwide.”

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.